Ionis reports positive Phase 3 results for olezarsen in sHTG: 72% triglyceride drop, 85% pancreatitis reduction

IONIS PHARMACEUTICALS INC

• Olezarsen achieved 72% placebo-adjusted mean reduction in fasting triglycerides in Phase 3 CORE study (p<0.0001)
• Olezarsen reduced acute pancreatitis events by 85% (p=0.0002) in pooled analysis of CORE and CORE2 studies
• Over 90% of patients from CORE/CORE2 enrolled in open-label extension study
• Ionis plans to submit sNDA to FDA for olezarsen in sHTG by end of year